Psychosocial and biological treatment considerations for the paraphilic and nonparaphilic sex offender.
D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use*; D001348:Aversive Therapy / Q000379:methods*; D001521:Behavior Therapy / Q000379:methods*; D002648:Child; D002650:Child Abuse, Sexual / Q000331:legislation & jurisprudence / Q000517:prevention & control / Q000523:psychology; D003534:Cyproterone / Q000627:therapeutic use*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D010262:Paraphilic Disorders / Q000209:etiology / Q000523:psychology / Q000628:therapy*; D011902:Rape / Q000331:legislation & jurisprudence / Q000523:psychology; D055502:Secondary Prevention; D012742:Sex Offenses / Q000331:legislation & jurisprudence* / Q000523:psychology; D012951:Socialization
D000726:Androgen Antagonists; D017258:Medroxyprogesterone Acetate; D003534:Cyproterone; D016729:Leuprolide